What is Community-Acquired Bacterial Pneumonia (CABP)?
Community-Acquired Bacterial Pneumonia (CABP) is defined as an acute bacterial infection of the pulmonary parenchyma associated with chest pain, cough, sputum production, difficulty breathing, chills, rigors, fever, or hypotension and is accompanied by the presence of a new lobar or multilobar infiltrate on a chest radiograph.
How is Community-Acquired Bacterial Pneumonia caused?
Common typical bacterial pathogens that cause CABP include Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. Atypical bacterial pathogens such as Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila also cause CABP.
How is Community-Acquired Bacterial Pneumonia treated?
CABP treatment aims include microbiological eradication, clinical improvement, minimization of hospital stay, and prevention of reinfection. Guideline-directed treatment reduces the mortality in CABP.
How has Community-Acquired Bacterial Pneumonia (CABP) affected population?
- CABP affects 3–4 million people each year worldwide, with high morbidity and mortality, particularly among elderly patients.
- Males are more affected with Community-Acquired Bacterial Pneumonia in comparison to females.
How CABP epidemiology is segmented?
Community-Acquired Bacterial Pneumonia epidemiology is segmented in the 7MM from 2017–2030 study period as:-
- Total Incident Cases of Community-Acquired Bacterial Pneumonia (CABP)
- Gender-specific Incident Cases of Community-Acquired Bacterial Pneumonia
- Age-specific Incident Cases of CABP
- Diagnosed and Treatable Cases of Community-Acquired Bacterial Pneumonia
DelveInsight's "Community-Acquired Bacterial Pneumonia (CABP) Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia (CABP), historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia (CABP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The CABP market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, current and forecasted Community-Acquired Bacterial Pneumonia market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Community-Acquired Bacterial Pneumonia (CABP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
To know more, request sample pages @ Community-Acquired Bacterial Pneumonia Market Landscape
Community-Acquired Bacterial Pneumonia Market Outlook
According to DelveInsight, CABP market in 7MM is expected to change in the study period 2017-2030.
The Community-Acquired Bacterial Pneumonia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted CABP market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Community-Acquired Bacterial Pneumonia (CABP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
How many biotechnological companies are developing CABP drugs?
Community-Acquired Bacterial Pneumonia market dynamics is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as Combioxin, BioAegis Therapeutics, Biotest, Tigenix, and others are involved in developing drugs for Community-Acquired Bacterial Pneumonia.
Scope of the Report
- The report covers the descriptive overview of Community-Acquired Bacterial Pneumonia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the CABP epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for CABP are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Community-Acquired Bacterial Pneumonia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Community-Acquired Bacterial Pneumonia market.
Request sample pages for more information on CABP Market Size
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email:Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
